MetaCap

Canton Strategic (CNTN) vs Minerva Neurosciences (NERV)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Minerva Neurosciences (NERV) has outperformed Canton Strategic (CNTN) over the past year, losing 49.2% versus a loss of 50.6%. Minerva Neurosciences is the larger company by market cap ($99.7 million vs $98.8 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CNTN-50.61%NERV-49.24%
+132%+37%-59%
Nov 21, 20251 yearNov 20, 2026
CNTN-99.89%NERV-70.06%
+111%+1%-110%
Jan 10, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CNTN versus NERV key metrics
MetricCNTNNERV
Share price$1.21$2.00
Market cap$98.78M$99.67M
1-day change-1.63%-5.66%
YTD return-60.07%-50.25%
1-year return-50.61%-49.24%
5-year return—-76.42%
P/E ratio (TTM)20.17—
EPS (TTM)$0.06$-33.83
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-35.92M$-293.42M
52-week high$5.83$8.80
52-week low$1.19$1.96
Distance from 52-week high-79.25%-77.27%
Analyst consensus—buy
Avg. price target upside—+416.50%
Average volume763.63K164.71K
Shares outstanding81.64M49.84M
Employees127
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Canton Strategic

CNTN stock →

Canton Strategic Holdings, Inc. focuses on advancing institutional blockchain adoption and digitizing financial markets in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees

About Minerva Neurosciences

NERV stock →

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia.

Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees

CNTN vs NERV FAQ

Which is bigger, Canton Strategic or Minerva Neurosciences?

Minerva Neurosciences (NERV) is larger, with a market capitalization of $99.67M compared with $98.78M for Canton Strategic (CNTN).

Which stock has performed better over the past year, CNTN or NERV?

NERV returned -49.24% over the past 12 months, compared with -50.61% for CNTN (price return, excluding dividends). Past performance does not predict future results.

Are Canton Strategic and Minerva Neurosciences in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons